Search

Your search keyword '"Roberta S. Batorsky"' showing total 4 results
Start Over Author "Roberta S. Batorsky" Publication Year Range Last 3 years
4 results on '"Roberta S. Batorsky"'

1. Supplementary Figure 2 from Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885

Author

Pearl S. Huang, David A. Tuveson, Michael M. Morrissey, Meenhard Herlyn, Keiran S.M. Smalley, Rooja G. Contractor, Jerry L. Adams, Ami S. Lakdawala, Lusong Luo, Michael D. Schaber, Cynthia M. Rominger, Earl W. May, Thomas J. Stout, David Chau, Jae Lee, Julie C. Lougheed, Florian Karreth, Lifu Wang, Erin Hugger, David M. Wilson, Andrew K. Takle, David W. Rusnak, Rakesh Kumar, Shu Yun Zhang, Hieu T. Do, Maureen L. Ho, Roberta S. Batorsky, Denis R. Patrick, and Alastair J. King

Abstract

Supplementary Figure 2 from Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885

Published
2023

2. Supplementary Figure 3 from Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885

Author

Pearl S. Huang, David A. Tuveson, Michael M. Morrissey, Meenhard Herlyn, Keiran S.M. Smalley, Rooja G. Contractor, Jerry L. Adams, Ami S. Lakdawala, Lusong Luo, Michael D. Schaber, Cynthia M. Rominger, Earl W. May, Thomas J. Stout, David Chau, Jae Lee, Julie C. Lougheed, Florian Karreth, Lifu Wang, Erin Hugger, David M. Wilson, Andrew K. Takle, David W. Rusnak, Rakesh Kumar, Shu Yun Zhang, Hieu T. Do, Maureen L. Ho, Roberta S. Batorsky, Denis R. Patrick, and Alastair J. King

Abstract

Supplementary Figure 3 from Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885

Published
2023

3. Supplementary Figure 1 from Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885

Author

Pearl S. Huang, David A. Tuveson, Michael M. Morrissey, Meenhard Herlyn, Keiran S.M. Smalley, Rooja G. Contractor, Jerry L. Adams, Ami S. Lakdawala, Lusong Luo, Michael D. Schaber, Cynthia M. Rominger, Earl W. May, Thomas J. Stout, David Chau, Jae Lee, Julie C. Lougheed, Florian Karreth, Lifu Wang, Erin Hugger, David M. Wilson, Andrew K. Takle, David W. Rusnak, Rakesh Kumar, Shu Yun Zhang, Hieu T. Do, Maureen L. Ho, Roberta S. Batorsky, Denis R. Patrick, and Alastair J. King

Abstract

Supplementary Figure 1 from Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885

Published
2023

4. Data from Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885

Author

Pearl S. Huang, David A. Tuveson, Michael M. Morrissey, Meenhard Herlyn, Keiran S.M. Smalley, Rooja G. Contractor, Jerry L. Adams, Ami S. Lakdawala, Lusong Luo, Michael D. Schaber, Cynthia M. Rominger, Earl W. May, Thomas J. Stout, David Chau, Jae Lee, Julie C. Lougheed, Florian Karreth, Lifu Wang, Erin Hugger, David M. Wilson, Andrew K. Takle, David W. Rusnak, Rakesh Kumar, Shu Yun Zhang, Hieu T. Do, Maureen L. Ho, Roberta S. Batorsky, Denis R. Patrick, and Alastair J. King

Abstract

Oncogenic BRAF alleles are both necessary and sufficient for cellular transformation, suggesting that chemical inhibition of the activated mutant protein kinase may reverse the tumor phenotype. Here, we report the characterization of SB-590885, a novel triarylimidazole that selectively inhibits Raf kinases with more potency towards B-Raf than c-Raf. Crystallographic analysis revealed that SB-590885 stabilizes the oncogenic B-Raf kinase domain in an active configuration, which is distinct from the previously reported mechanism of action of the multi-kinase inhibitor, BAY43-9006. Malignant cells expressing oncogenic B-Raf show selective inhibition of mitogen-activated protein kinase activation, proliferation, transformation, and tumorigenicity when exposed to SB-590885, whereas other cancer cell lines and normal cells display variable sensitivities or resistance to similar treatment. These studies support the validation of oncogenic B-Raf as a target for cancer therapy and provide the first evidence of a correlation between the expression of oncogenic BRAF alleles and a positive response to a selective B-Raf inhibitor. (Cancer Res 2006; 66(23): 11100-5)

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results